Quality of Life Issues



Nowadays, the main method for assessing the efficiency of pharmacologic therapies are the randomized controlled trials (RCTs), which are regarded as an objective measure of the biologic response of the patients to a given treatment. However, beside quantifying therapeutic responses, there are many other subjective factors (emotional factors such as depression or anxiety, ability to perform daily activities at the workplace or at home, changes in eating/sleeping, social, familiar, and sexual habits), which are difficult to assess using quantitative methods. Both dyspepsia and quality of life (QoL) are ill-defined terms [1, 2]. Physicians traditionally prefer to use objective methods to diagnose and monitor treatment responses. However, many gastrointestinal diseases have a high symptom burden and enormous health-care costs but little objective evidence of the disease; this is especially true for the large group of functional disorders to which dyspepsia belongs [3, 4].


Functional dyspepsia Helicobacter pylori Patient-reported outcome measures Quality of life Questionnaires Randomized controlled trials 



The author is indebted to Douglas Arnott (EDMF Translation Bureau, Etyek, Hungary) for correcting the English manuscript for this chapter and chapter “Prognosis.” The secretarial help of Mrs. Jolán Józan (Semmelweis University, Department of Physiology, Budapest, Hungary) is highly appreciated.


  1. 1.
    Fayer PM, Machin D, editors. Quality of life. Assessment, analysis and interpretation. Chichester: Wiley; 2000.Google Scholar
  2. 2.
    Bytzer P, Tally NJ. Dyspepsia. Ann Intern Med. 2001;134:815–22.PubMedGoogle Scholar
  3. 3.
    Wiklund I. Patient-reported outcomes. In: Talley NJ, Locke III GR, Saito YA, editors. GI epidemiology. Oxford: Blackwell; 2006. p. 24–30.Google Scholar
  4. 4.
    Creed F, Levy RL, Bradley LA, et al. Psychosocial aspects of functional gastrointestinal disoders. In: Drossman DA, Corazziari E, Spiller RC, Thompson WG, editors. The functional gastrointestinal disorders, Rome III. McLean, VA: Degnon Associates; 2006. p. 313–4. 318–21, 346–7.Google Scholar
  5. 5.
    Locke III GR. GI questionnaires. In: Talley NJ, Locke III GR, Saito YA, editors. GI epidemiology. Oxford: Blackwell; 2006. p. 30–4.Google Scholar
  6. 6.
    Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, editors. Introduction to meta-analysis. Chichester: Wiley; 2009.Google Scholar
  7. 7.
    Yacavone RF, Locke 3rd GR, Provenzale DT, Eisen GM. Quality of life measurement in gastroenterology: what is available? Am J Gastroenterol. 2001;96:285–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Dimenas E, Glise H, Hallerback B, Hernquist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–52.PubMedCrossRefGoogle Scholar
  9. 9.
    el-Omar EM, Banerjee S, Wirz A, McColl KE. The Glasgow Dyspepsia Severity Score: a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol. 1996;8:967–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Moayyedi P, Duffett S, Braunholtz D, et al. The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther. 1998;12:1257–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Wiklund I, Junghard O, Grace E, et al. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998; 583:41–9.Google Scholar
  12. 12.
    Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999;231:48–54.PubMedGoogle Scholar
  13. 13.
    Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut. 1999;44:527–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther. 1999;13:225–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Bamfi F, Oliveri A, Arpinelli F, et al. Measuring quality of life in dyspeptic patients: development and validation of a new specific health status questionnaire: final report from the Italian QPD project involving 4000 patients. Am J Gastroenterol. 1999;94:730–8.PubMedGoogle Scholar
  16. 16.
    Cook KF, Rabeneck L, Campbell CJ, Wray NP. Evaluation of a multidimensional measure of dyspepsia-related health for use in a randomized clinical trial. J Clin Epidemiol. 1999;52:381–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Leidy NK, Farup C, Rentz AM, Ganoczy D, Koch KL. Patient-based assessment in dyspepsia:development and validation of Dyspepsia Symptoms Severity Index (DSSI). Dig Dis Sci. 2000;45:1172–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther. 2001;15:207–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol. 2001;54:755–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Tian XP, Li Y, Liang FR, et al. Translation and validation of the Nepean Dyspepsia Index for functional dyspepsia in China. World J Gastroenterol. 2009;15:3173–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Veldhuyzen van Zanten SJ, Chiba N, Amstrong D, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006;23:521–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lee EH, Hahm KB, Lee HJ, et al. Development and validation of a functional dyspepsia-related quality of life (FD-QOL) scale in South Korea. J Gastroenterol Hepatol. 2006;21:268–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Mahadeva S, Wee HL, Goh KL, Thumboo L. The EQ-5D (Euroqol) is a valid generic instrument for measuring quality of life in patients with dyspepsia. BMC Gastroenterol. 2009;9:20.PubMedCrossRefGoogle Scholar
  24. 24.
    Talley NJ, Ruff K, Jiang X, Jung HK. The Rome III Classification of dyspepsia: will it help research? Dig Dis Sci. 2008;26:203–9.CrossRefGoogle Scholar
  25. 25.
    Moayyedi P, Forman D, Braunholz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol. 2000;95:1448–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Moayyedi P, Feltbower L, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet. 2000;355:1665–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009;21:378–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Meineche-Schmidt V, Talley NJ, Pap Á, et al. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol. 1999;34:566–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Buzás GM. Quality of life in patients with functional dyspepsia: short- and long- term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisparide therapy: a prospective, parallel-group study. Curr Ther Res. 2006;67:305–20.CrossRefGoogle Scholar
  30. 30.
    Haag S, Senf W, Häuser W, et al. Impairement of health-related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety. Aliment Pharmacol Ther. 2008;27:561–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Talley NJ, Locke III GR, Lahr BD, et al. Functional dyspepsia, delayed gastric empyting and impaired quality of life. Gut. 2006;55:933–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Holtmann G, Adam B, Haag S, Collet W, Grünewald E, Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther. 2003;18:1099–105.PubMedCrossRefGoogle Scholar
  33. 33.
    Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005;100:1477–88.PubMedCrossRefGoogle Scholar
  34. 34.
    Holtmann G, Talley NJ, Liebregtd T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832–40.PubMedCrossRefGoogle Scholar
  35. 35.
    van Zanten SV, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized placebo-controlled “ENTER” trial. Am J Gastroenterol. 2006;101:2096–106.PubMedCrossRefGoogle Scholar
  36. 36.
    Raedsch R, Hanisch J, Bock P, Sibaev A, Vinson B, Gundermann KJ. Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia: a retrolective cohort study. Z Gastroenterol. 2007;45:1041–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Talley NJ, Tack J, Ptak K, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57:740–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Vakil N, Kianifard F, Bottoli I. Exploratory study of tegaserod for dyspepsia in women receving ppis for heartburn. Arch Drug Inf. 2008;1:79–88.PubMedCrossRefGoogle Scholar
  39. 39.
    van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008;6:746–52.PubMedCrossRefGoogle Scholar
  40. 40.
    Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate im improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104:2779–87.PubMedCrossRefGoogle Scholar
  41. 41.
    Park YC, Kang W, Choi SM, Son CG. Evaluation of manual acupuncture at classical and nondefined points for treatment of functional dyspepsia: a randomized-controlled trial. J Altern Complement Med. 2009;15:879–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Braden B, Caspary W, Börner N, Vinson B, Schneider AR. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21:632–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21:688–96.PubMedCrossRefGoogle Scholar
  44. 44.
    Malfertheiner P, Mégraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;CD002096.Google Scholar

Copyright information

© Springer Science+Business Media LLC 2011

Authors and Affiliations

  1. 1.Department of GastroenterologyFerencváros Health Service Non-Profit LtdBudapestHungary

Personalised recommendations